Ajanta Pharma Limited (AJANTPHARM) — Announcement | 2 July 2026

· NSE Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings

Ajanta Pharma announced that its Paithan manufacturing facility in Maharashtra received a Voluntary Action Indicated classification from the US FDA following a cGMP inspection conducted between 13-21 April 2026. The company previously disclosed the inspection on 22 April 2026. The FDA report confirms compliance with current Good Manufacturing Practices standards for the site.

📄 View Original Announcement (PDF)

About Ajanta Pharma Limited (AJANTPHARM)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹39,694.55 Cr P/E: 37.6 ROE: 23.3% ROCE: 29.4%

View full AJANTPHARM stock details →

📡 Get AI alerts when AJANTPHARM files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track AJANTPHARM — Free

📊 More AJANTPHARM filings

See all AJANTPHARM filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when AJANTPHARM files new disclosures

Track AJANTPHARM filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track AJANTPHARM — Free

Free account · 2 AI queries/day